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Abstract
Poliomyelitis has afflicted humankind since antiquity, and for nearly a century now, we have known
the causative agent, poliovirus. This pathogen is an enterovirus that in recent history has been the
source of a great deal of human suffering. Although comparatively small, its genome is packed with
sufficient information to make it a formidable pathogen. In the last 20 years the Global Polio
Eradication Initiative has proven successful in greatly diminishing the number of cases worldwide
but has encountered obstacles in its path which have made halting the transmission of wild
polioviruses a practical impossibility. As we begin to realize that a change in strategy may be crucial
in achieving success in this venture, it is imperative that we critically evaluate what is known about
the molecular biology of this pathogen and the intricacies of its interaction with its host so that in
future attempts we may better equipped to more effectively combat this important human
pathogen.
Background
The word poliomyelitis, the medical term used to describe
the effect of poliovirus (PV) on the spinal cord, is derived
from the Greek words for gray (polio) and marrow (mye-
lon). The first known clinical description of poliomyelitis
is attributed to Michael Underwood, a British physician,
who in 1789 reported observing an illness which
appeared to target primarily children and left those
afflicted with residual debility of the lower extremities. In
subsequent years, additional cases of poliomyelitis would
be reported. Initial outbreaks in Europe were documented
in the early 19th century and outbreaks in the United
States were first reported in 1843. However, it was not
until the early 20th century that the number of paralytic
poliomyelitis cases reached epidemic proportions.
In 1938, in efforts to support care for patients with polio-
myelitis as well as fund research to combat the illness, the
National Foundation for Infantile Paralysis (now the
March of Dimes) was established. The number of paralytic
cases in the United States, estimated to have been in excess
of 21,000, peaked in 1952. Fortunately, on April 12,
1955, the March of Dimes declared that the Salk polio
vaccine was both safe and effective. Then, in 1963, the
development of a second vaccine, the Sabin polio vaccine,
was announced. With the introduction of effective vac-
cines, the incidence of poliomyelitis rapidly declined.
Indeed, in the United States, the last case of poliomyelitis
due to infection with wild type (wt) virus was reported in
1979. Less than a decade later, in 1988, the World Health
Organization (WHO) launched a global campaign to
eradicate PV.
Since initial descriptions of poliomyelitis were first docu-
mented to the present time, innumerable milestones have
been reached in understanding the molecular biology of
PV and the pathogenesis of poliomyelitis. Such advances
have certainly led to the more effective management of
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poliomyelitis. Nonetheless, many questions remain
unanswered. One such question pertains to the determi-
nants of neuropathogenesis, specifically regions of the
virus genome important for aspects of virus replication in
the cells which it targets.
In this review, the current state of our understanding of
the molecular biology and pathogenesis of poliovirus, as
it relates to current eradication efforts, is explored.
Poliovirus classification
PV was discovered to be the causative agent of poliomye-
litis in 1909 by Karl Landsteiner and Erwin Popper, two
Austrian physicians [109]. Owing to the expression of
three unique sets of four different neutralization antigenic
determinants on the poliovirion surface referred to as N-
Ag1, 2, 3A, and 3B [110,155], the virus occurs in three
serotypes, termed types 1, 2, and 3, where the names
Mahoney, Lansing, and Leon designate a strain of each
serotype, respectively [21,98,125,137]. The polioviruses
are classified as members of the Picornaviridae, a large fam-
ily of small RNA viruses, consisting of nine genera: Enter-
ovirus,  Rhinovirus,  Cardiovirus,  Aphthovirus,  Hepatovirus,
Parechovirus, Erbovirus, Kobuvirus, and Teschovirus  (Table
1). The Enterovirus  genus, to which the polioviruses
belong, can be further subdivided into eight clusters (i.e.,
Poliovirus,  Human enterovirus A,  Human enterovirus B,
Human enterovirus C, Human enterovirus D, Simian enterovi-
rus A, Bovine enterovirus, and Porcine enterovirus B) (Table
2), which include predominantly human pathogens
exhibiting marked variation in the disease syndromes they
produce.
Admittedly, the initial classification of human enterovi-
ruses was based on the clinical manifestations observed in
human infections as well as on the pathogenesis in intrac-
ranially- and subcutaneously-inoculated experimental
suckling mice. The four categories into which human
enteroviruses were subdivided were: (1) polioviruses,
which caused flaccid paralysis (poliomyelitis) in humans
but not in suckling mice lacking CD155; (2) coxsackie A
viruses (CAV), which were linked to human central nerv-
ous system (CNS) pathology and skeletal muscle inflam-
mation (myositis) as well as acute flaccid paralysis in
suckling mice; (3) coxsackie B viruses (CBV), associated
with ailments of the human cardiac and central nervous
systems, and necrosis of the fat pads between the shoul-
ders, focal lesions in skeletal muscle, brain, and spinal
cord, as well as spastic paralysis in the suckling mouse
experimental model; and (4) echoviruses, which were not
originally associated with human disease nor with paraly-
sis in mice [41,121,201]. With groundbreaking advances
in molecular biology, a modified classification stratagem
has evolved. Under the new scheme, human enteroviruses
are subdivided into five species: Poliovirus  and  Human
enterovirus A, B, C, and D. The three PV serotypes (i.e., PV1,
2, and 3) constitute the species Poliovirus, and 11 cox-
sackie A virus serotypes (i.e., CAV1, 11, 13, 15, 17, 18, 19,
20, 21, 22, and 24) constitute the Human enterovirus C
(HEV-C) [96] (Table 2). But recently, the Executive Com-
mittee of the International Committee on Taxonomy of
Viruses (ICTV) has endorsed a proposal, which awaits rat-
ification by the ICTV membership, to move the poliovi-
ruses into the Human enterovirus C species. On the basis of
genome sequences, the C-cluster human enteroviruses
bearing the greatest degree of relatedness to the poliovi-
ruses are CAV11, CAV17, and CAV20 [31]. Indeed, genet-
ically, these three C-cluster coxsackie A viruses differ
notably from the polioviruses only in the structural (P1)
capsid region [31].
The poliovirus genome
The genome of the polioviruses as well as that of members
of the Human enterovirus C cluster is approximately 7400
nucleotides (nt) in length (PV, 7441 nt) and composed of
single-stranded RNA consisting of three distinct regions: a
relatively long 5'NTR (PV, 742 nt) that is covalently linked
to the virus-encoded 22-amino acid long VPg protein
[110,196]; a single open reading frame (ORF) encoding
the viral polyprotein; and a comparatively short 3'NTR
followed by a virus-encoded poly(A) tract of variable
length (PV, 60 adenine residues) [47,97,163,182,202]
(Fig. 1A).
Table 1: Classification within the Picornaviridae
Genus Type Species Serotypes
Enterovirus Poliovirus 3
Human enterovirus A 17
Human enterovirus B 56
Human enterovirus C 13
Human enterovirus D 3
Simian enterovirus A 1
Bovine enterovirus 2
Porcine enterovirus B 2
Rhinovirus Human rhinovirus A 74
Human rhinovirus B 25
Cardiovirus Encephalomyocarditis virus 1
Theilovirus 3
Aphtovirus Foot-and-mouth disease virus 7
Equine rhinitis A virus 1
Hepatovirus Hepatitis A virus 1
Avian encephalomyelitis-like virus 1
Parechovirus Human parechovirus 3
Ljungan virus 2
Erbovirus Equine rhinitis B virus 2
Kobuvirus Aichi virus 1
Teschovirus Bovine kobuvirus 1
Porcine teschovirus 11Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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The 5'NTR is predicted to harbor a significant degree of
complex secondary structure [1,158,179] (Fig. 2). Com-
puter analysis has predicted six domains (domains I-VI)
within the 5'NTR, many of which have been validated by
genetic and biochemical analyses [53] as well as visual-
ized by electron microscopy [10]. In this region of the
genome, eight cryptic AUG triplets have been identified
which precede the initiation codon at nt 743. This seg-
ment of the genome can be further subdivided into: (i) the
5'-terminal cloverleaf, an indispensable cis-acting element
in viral RNA replication [3,113,144,147] as well as in reg-
ulating the initiation of translation; and (ii) the IRES
[197], which mediates cap-independent translation of the
viral mRNA by facilitating initiation of translation inde-
pendent of a capping group and even a free 5' end
[36,90,91,147,149,150].
In contrast to the 5'NTR, comparatively less is known
about the 3'NTR. Nonetheless, this region is known to be
poly-adenylated and predicted to exhibit conserved sec-
ondary structures consisting of two hairpins [89,160].
Moreover, evidence indicates that it has a functional role
in RNA replication [31,32,50,89,108,123,157,159,160].
Specifically, it has been shown that while deletion of the
3'NTR has only minimal effects on the ability of PV to
propagate in HeLa cells, the ability of the virus to propa-
gate in cells of neuronal origin is markedly reduced both
in vitro and in vivo [31].
The 250-kDa polyprotein encoded by the single ORF can
be further subdivided into regions denoted P1, P2, and
P3, encoding the structural and nonstructural proteins.
Following translation of pUp-terminated mRNA
[81,134], proteolytic cleavage of the unstable "polypro-
tein" by virus-encoded proteinases, 2Apro and 3C/3CDpro
in cis and in trans [78] (Fig. 1B), gives rise to proteins with
functions in viral proliferation. Processing of the polypro-
tein is thought to proceed in accordance to a pathway
established by protein folding resulting in masking of cer-
tain cleavage sites and by amino acid sequences adjoining
the scissile bond [78] The first cleavage of the genomic
polyprotein at a tyrosine-glycine dipeptide is catalyzed by
the 2A proteinase and results in release of a 97-kDa poly-
protein consisting of the P1 structural segment of the
genome [190]. Subsequent cleavages of the P1 precursor
into stable end products VP0, VP3, and VP1 is mediated
by the 3CD proteinase [203]. Cleavage of VPO into capsid
proteins VP4 and VP2 occurs during maturation of the vir-
ion and is mediated by an unknown mechanism that has
been hypothesized to be viral proteinase independent
[77]. The cleavage of P2 and P3 precursors into stable end
products [2Apro, 2B, 2BC, 2C, 3A, 3AB, 3B (VPg), 3C/
3CDpro, and 3Dpol] at glutamine-glycine dipeptides is cat-
alyzed by the 3Cpro/3CDpro [76].
The cellular life cycle of poliovirus
The life cycle of PV occurs within the confines of the cyto-
plasm of infected cells (Fig. 3). It is initiated by attach-
ment of the poliovirion to the N-terminal V-type
immunoglobulin-like domain of its cell surface receptor,
the human PV receptor (hPVR) or CD155 [99,122,175].
Release of the virus RNA into the cell cytoplasm (uncoat-
ing) is thought to occur by destabilization of the virus cap-
sid secondary to CD155-mediated release of the
myristoylated capsid protein VP4 and of the putative N-
terminal amphipathic helix of VP1 from deep within the
virion [reviewed in [84]]. Subsequently, the myristoylated
VP4 and VP1 amphiphatic helix are thought to insert into
the cell membrane [58], thereby leading to the creation of
pores in the cell membrane through which the virus RNA
may enter the cytoplasm. Alternatively, since the virus can
be found on endosomes [101,102,139], others believe the
virus is taken up by receptor-mediated endocytosis. How-
ever, both classic endocytotic pathways (clathrin-coated
pits or caveoli) as the means of uptake have been excluded
[45,84]. Additionally, if entry of the virus involves endo-
Table 2: Classification within the Enterovirus Genus
Clusters Serotypes Receptors
Poliovirus poliovirus 1 (PV1), PV2, PV3 CD155 [122]
Human enterovirus A coxsackievirus A2(CV-A2) - CV-A8, CV-A10, CV-A12, CV-A14, CV-A16
enterovirus 71 (EV-71), EV-76, EV-89 - EV-92
Human enterovirus B coxsackievirus B1 (CV-B1) - CV-B6 CAR,[13] DAF[12]
CV-A9 αvβ3 integrin[169]
echovirus 1 (E-1) - E-7, E-9, E-11 - E-21, E-24 - E-27, E-29 - E-33
EV-69, EV-73 - EV-75, EV-77 - EV-88, EV-93, EV-97, EV-98, EV-100, EV-101
Human enterovirus C CV-A1, CV-A11, CV-A13, CV-A17, CV-A19, CV-A22, CV-A24, ICAM-1 (CV-A21[176])
EV-95, EV-96, EV-99, EV-102
Human enterovirus D EV-68, EV-70, EV-94
Simian enterovirus A simian enterovirus A1 (SEV-A1)
Bovine enterovirus bovine enterovirus 1 (BEV-1), BEV-2
Porcine enterovirus B porcine enterovirus 9 (PEV-9), PEV-10Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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somes, acidification of this compartment is not necessary
for release of the virus RNA into the cytoplasm [70]. Thus
the exact mechanism by which the virus releases its RNA
genome into the cytoplasm of infected cells remains to be
elucidated.
Nonetheless, once in the cytoplasm of infected cells, an
unknown cellular phosphodiesterase is believed to cleave
the 5'NTR-linked viral protein VPg. This process is fol-
lowed by initiation of translation of the RNA genome by
host cell ribosomes [196]. Concurrently, shut off of cap-
dependent host cell translation occurs by 2Apro-mediated
cleavage of the eukaryotic translation initiation factor 4G
(eIF4G), an element of the cap recognizing complex eIF4F
[100,181,193]. Interestingly, a byproduct of eIF4G cleav-
age binds viral RNA and promotes IRES-dependent trans-
lation of the viral polyprotein [140]. Moreover, inhibition
of host cell transcription occurs via inactivation of tran-
scription factor TFIIIC [40] and cleavage of the TATA box
binding protein (TBP) by 3Cpro [199].
Genomic structure of poliovirus type 1 (Mahoney) [PV1(M)] and proteolytic processing of its polyprotein Figure 1
Genomic structure of poliovirus type 1 (Mahoney) [PV1(M)] and proteolytic processing of its polyprotein. (A) The PV genome 
consists of a single-stranded, positive-sense polarity RNA molecule, which encodes a single polyprotein. The 5' non-translated 
region (NTR) harbors two functional domains, the cloverleaf and the internal ribosome entry site (IRES), and is covalently 
linked to the viral protein VPg. The 3'NTR is poly-adenylated. (B) The polyprotein contains (N terminus to C terminus) struc-
tural (P1) and non-structural (P2 and P3) proteins that are released from the polypeptide chain by proteolytic processing medi-
ated by virally-encoded proteinases 2Apro and 3Cpro/3CDpro to ultimately generate eleven mature viral proteins [197]. Three 
intermediate products of processing (2BC, 3CD, and 3AB) exhibit functions distinct from those of their respective final cleav-
age products.
= 2A      cleavage site pro
= 3C     /3CD     cleavage site pro pro
= Maturation cleavageVirology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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With the synthesis of virus proteins, replication of the
RNA begins. Initially, for the first three hours following
infection of a permissive host cell, the kinetics of RNA rep-
lication is exponential. This is followed by a linear phase
for one and a half hours, which ultimately enters a period
of rapid decay in the rate of synthesis [172]. The process
of RNA replication takes place in the cytoplasm on host
cell endoplasmic reticulum-derived rosette-like membra-
nous structures, the formation of which is induced by viral
proteins 2C and 2BC [14,38,188]. Subsequently, a hydro-
phobic domain in 3AB anchors this protein in the mem-
branes, and the affinity of 3AB for 3Dpol and 3CDpro
recruits the replication complex to this new sub-cellular
compartment. Within the confines of this micro-environ-
ment in the host cell cytoplasm, replication of the virus
RNA genome follows a complex pathway involving the
formation of intermediates – a replicative form, consisting
of double stranded RNA, and a replicative intermediate,
composed of a negative-strand partially hybridized to
multiple nascent positive-strands [reviewed in [197]].
Briefly, viral RNA replication starts with uridylylated VPg
(VPg-pU-pU)-primed synthesis of complementary nega-
tive-strand RNA molecules via the transcription of
poly(A) by the RNA dependent RNA polymerase 3Dpol.
The negative-strand RNA molecules then serve as tem-
plates for the synthesis of positive-strand RNA molecules
[145]. Newly synthesized positive-strand RNA molecules
can serve as mRNA templates for continued translation of
viral proteins or targeted as virus RNA molecules to be
encapsidated in progeny poliovirions by covalent linkage
of VPg to their 5' ends [135].
Encapsidation of VPg-linked positive-strand RNA mole-
cules, a process which constitutes the final steps in the cel-
lular life cycle of PV, appears to be linked to RNA synthesis
[6] at the interface of membranous structures in the cyto-
plasm of infected cells [153]. To start, 3CDpro cleaves the
P1 precursor polypeptide, thereby giving rise to proteins
Secondary structure of the PV1(M) 5'NTR Figure 2
Secondary structure of the PV1(M) 5'NTR. This genomic region has been divided into six domains (I to VI) [197], of which 
domain I constitutes the cloverleaf and the remaining domains (II to VI) comprise the IRES. Spacer sequences without complex 
secondary structure exist between the cloverleaf and the IRES (nt 89–123) and between the IRES and the initiation codon (nt 
620–742). Mutations in the 5'NTR of the Sabin PV type 1, 2, and 3 vaccine strains localizing to nucleotides 480 (A to G) [94], 
481 (A to G) [129], and 472 (C to U) [194], respectively, each denoted by a star, confer attenuation in the CNS and deficient 
replication in neuroblastoma cells [106, 107] as well as reduced viral RNA translation efficiency [184-186].
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VP0, VP1, and VP3, which assemble to form a protomer
[195]. Five protomers then aggregate thereby generating a
pentamer [156], of which twelve ultimately assemble to
constitute the procapsid [88]. The VPg-linked positive-
strand virus RNA may be encapsidated either by conden-
sation of pentamers about the viral RNA [65,154] or by
incorporation of the virus RNA into procapsids [88].
Cleavage of VPO into VP2 and VP4, possibly via an auto-
catalytic mechanism [84], finalizes virus assembly by sta-
bilizing the capsid and thereby converting the provirion
into a mature, infectious virus particle [85]. The mature
virus capsid is an icosahedron composed of sixty copies
each of VP1-VP4, and exhibiting five-, three-, and two-fold
axes of symmetry. The outer surface of mature virus capsid
is formed by capsid proteins VP1-3, while VP4 is found
internally [83].
The cellular life cycle of poliovirus Figure 3
The cellular life cycle of poliovirus. It is initiated by binding of a poliovirion to the cell surface macromolecule CD155, which 
functions as the receptor (1). Uncoating of the viral RNA is mediated by receptor-dependent destabilization of the virus capsid 
(2). Cleavage of the viral protein VPg is performed by a cellular phosphodiesterase, and translation of the viral RNA occurs by 
a cap-independent (IRES-mediated) mechanism (3). Proteolytic processing of the viral polyprotein yields mature structural and 
non-structural proteins (4). The positive-sense RNA serves as template for complementary negative-strand synthesis, thereby 
producing a double-stranded RNA (replicative form, RF) (5). Initiation of many positive strands from a single negative strand 
produces the partially single-stranded replicative intermediate (RI) (6). The newly synthesized positive-sense RNA molecules 
can serve as templates for translation (7) or associate with capsid precursors to undergo encapsidation and induce the matura-
tion cleavage of VP0 (8), which ultimately generates progeny virions. Lysis of the infected cell results in release of infectious 
progeny virions (9).Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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The last step in completion of the cellular life cycle, which
under experimental conditions in vitro lasts approximately
seven to eight hours, is release of mature, infectious polio-
virions through lysis of the infected cell. Upon release, on
the order of 1% of poliovirions will in turn initiate effec-
tive infections of permissive host cells [2].
The poliovirus 5' Non-Translated Region (5'NTR)
Given the genetic austerity exhibited by RNA viruses,
including the picornaviruses, it is surprising that they con-
tain relatively long 5'NTRs (10% of the genome for polio-
viruses). These long segments of RNA, however, are
packed with information displaying unique features. An
important feature of the PV genomic RNA, a mRNA, that
distinguishes it from most cellular mRNAs, is the absence
of a 7-methyl guanosine (m7G) cap structure, which in
cellular mRNAs interacts with the eIF4F cap-binding com-
plex early in translation initiation of cellular proteins. In
picornaviruses, the initiation of translation depends upon
the internal ribosomal entry site (IRES), a novel cis-acting
genetic element which functions as a docking site for host
cell ribosomes [90,150]. Evidence for IRES-mediated, cap-
independent translation of the picornavirus RNA genome
emerged from experiments utilizing dicistronic RNAs har-
boring the IRES of encephalomyocarditis virus (EMCV)
[90] or PV [150]. Jang and colleagues demonstrated that
nucleotides 260–484 in the 5'NTR of EMCV were neces-
sary for the efficient in vitro translation of artificial mono-
and dicistronic mRNAs in nuclease-treated HeLa cell
extracts and in rabbit reticulocyte lysates (RLLs) [90]. Sim-
ilarly, Pelletier and Sonenberg showed that under condi-
tions which inhibited host cell translation (in PV-infected
cells), translation of the second cistron, harboring the bac-
terial chloramphenicol acetyltransferase (CAT) gene, medi-
ated by the PV 5'NTR was unaffected while translation of
the first cistron containing the herpes simplex virus-1
(HSV-1) thymidine kinase (TK) gene did not occur [150].
Since their discovery, IRES elements have been found in
the genomes of other viruses [reviewed in [9]], including
all picornaviruses (e.g., foot and mouth disease virus,
FMDV [104]; hepatitis C virus, HCV [192]; and simian
immunodeficiency virus, SIV [141]). IRES elements have
also been discovered in cellular mRNAs of numerous
organisms, including those encoding: human amyloid β
A4 precursor protein [162]; fly transcription repressor
hairless [116]; rat growth factor receptor [67]; and yeast
transcriptional activator TFIID [87] [reviewed in [9]].
On the basis of sequence homology and comparisons of
predicted structure models, the IRES elements of most
picornaviruses have been classified as either type 1, exem-
plified by entero- and rhinoviruses, or type 2, typified by
cardio- and apthoviruses [reviewed in [197]]. The two
classes of IRES elements exhibit functional differences in
their ability to initiate translation in cell-free translation
systems such as RRLs and HeLa cell-free extracts. Type 2
IRES elements, exemplified by the EMCV IRES, initiate
translation efficiently in RLLs. In contrast, type 1 IRES ele-
ments, exemplified by the PV IRES, show a deficiency in
their ability to initiate translation in RLLs which is rescued
by the addition of cytoplasmic extract from HeLa cells
[30,46]. The difference in the ability of the type 2 IRES to
initiate translation under these conditions underscores
differences in host factors encountered by this class of
IRES in the two systems. This in turn is suggestive of vari-
ation in the efficiency of IRES-mediated translation
depending on the infected host cell, and consequently on
the ability of the virus to produce pathologic changes.
In addition to the IRES domain, the 5' and 3' boundaries
of which have been defined at about nt 134 and nt 556,
respectively, by deletion analysis in vitro [86,103,133], the
PV 5'NTR harbors signals important for replication of the
virus RNA genome. The 5'-terminal 88 nt of the 5'NTR
form a characteristic clover leaf structure, which has been
shown to be an indispensable cis-acting element in viral
RNA replication [3,144]. Additionally, the 5'NTR contains
two spacer regions. One lies between the cloverleaf and
the IRES (nt 89–123) and the other maps to the region
between the 3' end of IRES and the initiation codon of the
polyprotein (nt 640–742). The former is a sequence with-
out a formally ascribed function. The latter has been dem-
onstrated to be conserved in length (100–104 nt) albeit
not in sequence. In line with this observation, emerging
evidence indicates that the length of this spacer is impor-
tant for optimal viral protein synthesis as when short
open reading frames are introduced between the IRES and
the initiation codon viral protein synthesis in vitro and, in
some instances, neurovirulence are diminished [7]. Fur-
thermore, when this spacer region between the IRES and
the initiation codon is deleted, PV exhibits an att pheno-
type [180]. The function of this spacer, which is absent in
the closely related rhinovirus 5'NTRs, remains a mystery.
As emerging data from the Wimmer group [43] [Toyoda
H, Franco D, Paul A, Wimmer E, submitted] [De Jesus N,
Jiang P, Cello J, Wimmer E, unpublished] indicates, the
short spacer between the cloverleaf and the IRES is loaded
with genetic information essential for properties charac-
teristic of PV.
Interaction of trans-acting factors with the poliovirus 
5'NTR
IRES-mediated translation of picornavirus RNAs involves
interactions with canonical, standard eukaryotic transla-
tion initiation factors (e.g., eIF2A) as well as non-canoni-
cal, cellular trans-acting factors that play different roles in
cellular metabolism (discussed below). Experimental
techniques employed to identify host cell factors that
interact with the PV 5'NTR include: RNA electrophoretic
mobility shift assay, UV-mediated crosslinking of proteinsVirology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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to RNA, and biochemical fractionation in junction with
supplementation assay. Indeed, while their abundance in
cells targeted by PV remains to be characterized, a number
of cellular proteins have been found to interact with the
PV 5'NTR. These include: eIF2A [44]; eIF4G [161]; autoan-
tigen La [119]; poly(rC) binding proteins 1 and 2 (PCBP1
and PCBP2) [59,144]; pyrimidine tract-binding protein
(pPTB) [79,80,152]; p97/upstream of N-ras (UNR) [29];
p48/50, p38/39, and p35/36 [52,62,75,130]; p60 [75];
and nucleo-cytoplasmic SR protein 20 (Srp20) [11].
As mentioned above, the only eukaryotic translation initi-
ation factors that have been demonstrated to interact with
the PV 5'NTR are eIF2A and eIF4G. Specifically, eIF2A
complexes with nt 97–182 of the PV 5'NTR [45], and dele-
tion of a 40 amino acid region of eIF4G (642–681) sub-
stantially diminishes PV translation initiation presumably
by interference with the ribosome scanning process that
propels PV IRES-driven translation [161].
Among the numerous cellular proteins hypothesized to be
involved in translation of the viral RNA and which have
been subjected to functional analyses are the following:
PCBP1, PCBP2, La, pPTB, p97/UNR [reviewed in [5]], and
Srp20 [11]. PCBP1 and PCBP2 are cellular proteins each
harboring three K homology (KH) RNA-binding
domains. Initially termed p38, PCBP was found to inter-
act with stem-loop IV of the PV IRES. Subsequently, PCBP
was found to have affinity for stem-loop I of the 5'NTR
(the cloverleaf) [59,144]. Disruption of the interaction
between PCBP and stem-loop IV in vitro by mutations in
stem-loop IV, depletion of PCBP from HeLa cell-free
extracts, and injection of anti-PCBP antibodies into Xeno-
pus laevis oocytes resulted in reduced translation of the
viral RNA [17-19,59]. Analogously, evidence suggests that
the interaction between PCBP and the cloverleaf (specifi-
cally stem-loop B) is also necessary for efficient transla-
tion of the virus RNA [60,178]. Stem-loop D of the
cloverleaf RNA binds the viral protein 3CD (and, very
poorly, 3Cpro). The cloverleaf, PCBP, and 3CD for a ter-
nary complex that is essential for initiation of plus-strand
RNA synthesis [3,4,48,168]. It has been hypothesized to
be involved in a switch mechanism governing use of the
viral RNA as either a template for translation or replica-
tion. Binding of 3CD to a complex formed by the clover-
leaf RNA and PCBP inhibits translation in a cell-free
extract and is hypothesized to promote replication,
thereby providing a mechanism to ensure an adequate
balance between these two processes. Incompatibility of
the cloverleaf RNA with the viral 3CD, as in the context of
chimeras, would be expected to result in decreased virus
viability. Indeed, while it has been shown that a virus con-
taining the 5'NTR of CB3 (nt 1–625) and remaining parts
of the genome from PV1(M) was viable [92], a virus con-
taining the 5'NTR of human rhinovirus 14 (HRV14) and
the remainder parts of the genome from PV3, exhibited a
lethal phenotype, because the PV 3CD was unable to
interact effectively with the HRV14 stem-loop D [168]. In
the latter, the virus was rescued by insertion of two
nucleotides into stem-loop D (CUAC60GG61) of the
HRV14 cloverleaf [167].
The nuclear protein La is an autoantigen targeted by anti-
bodies produced by patients with autoimmune disorders
such as systemic lupus erythematous and Sjogren's syn-
drome. Normally, it functions in termination of RNA
polymerase III transcription [68,69]. First characterized as
HeLa cell protein p52, La is found in HeLa cell-free
extracts but not in RLLs. Supplementation of RLLs with La
has been demonstrated to stimulate translation of PV
RNA [120].
The nuclear protein polypyrimidine tract-binding protein
(PTB), also known as hnRNP 1, which plays a role in alter-
native splicing of the cellular pre-mRNA [61,66,143],
associates with three sites within the PV 5'NTR (nt 70–
286, nt 443–539, and nt 630–730) as determined by UV-
crosslinking [80]. An attenuating mutation, C472U,
reduced the affinity of the PV 5'NTR to pPTB in neuroblas-
toma cells (SH-SY5Y) without disrupting this interaction
in HeLa cells [74]. nPTB, a neuronal-cell specific homo-
logue of PTB, was later described to bind less efficiently to
the PV IRES in the presence of the C472U attenuating
mutation [73].
The cytoplasmic RNA-binding protein UNR was originally
identified as p97 in HeLa cells and lacking in RLLs. Studies
in which endogenous expression of the unr gene was dis-
rupted by homologous recombination, transient expres-
sion of UNR effectively reestablished efficient translation
by human rhinovirus and PV IRESs [28].
Lastly, Srp20 is a member of the SR family of splicing reg-
ulators. Recently, it has been found to interact with PBCP2
[11], a cellular RNA-binding protein that (as discussed
above) binds to sequences within the PV IRES and is nec-
essary for translation of the viral RNA. Bedard and col-
leagues [11] have shown that PV translation is inhibited
by depletion of Srp20 in HeLa cell extracts and dimin-
ished by down-regulation of Srp20 protein levels by RNA
interference in vivo. Whether Srp20 interacts directly with
IRES sequences was not determined.
Poliovirus pathogenesis
PV tropism is limited to humans and non-human pri-
mates. In its natural host, PV transmits via the fecal-oral
route. To date, the specific sites and cell types in which the
virus initially replicates following entry into the host
remain enigmatic. Nevertheless, the ability to isolate virus
from the lymphatic tissues of the gastrointestinal tract,Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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including the tonsils, Peyer's patches of the ileum, and
mesenteric lymph nodes [24,25,106,173,174], as well as
the feces [106,174], prior to the onset of illness suggests
susceptible cells in these tissues may be sites of primary
replication. Following initial replication of the virus in
susceptible cells of the pharynx and gastrointestinal tract,
in the majority of infected individuals a minor, transient
viremia, but no neurologic complications, will develop.
As the infection progresses, the virus will spread further to
other sites of the reticuloendothelial system. Conse-
quently, the great majority of PV infections, nearly 95%,
including almost all infections in which a minor viremia
develops, are 'innaparent' or asymptomatic. In 4–8% of
infected individuals that develop primary viremia, a sec-
ondary, major viremia often associated with a 'minor,
non-specific illness' will ensue. Also known as abortive
poliomyelitis, the clinical manifestations of this 'minor,
non-specific illness' include many signs and symptoms
generally associated with other viral illnesses: (a) an upper
respiratory infection, characterized by sore throat and
fever; (b) a gastrointestinal illness, presenting with nau-
sea, vomiting, abdominal discomfort, and constipation or
(infrequently) diarrhea; and/or (c) an illness mimicking
influenza, marked by headache, myalgia, and generalized
malaise [24,106,174]. In turn, a minute segment of
infected individuals that experience major viremia will
progress to develop signs and symptoms indicating PV
invasion of the CNS, as characterized by non-paralytic
aseptic meningitis or paralytic poliomyelitis. Non-para-
lytic aseptic meningitis occurs in 1–2% of PV infections
and is associated with rigidity of the neck, back, and lower
limbs as well as an augmented number of leukocytes (10–
200 cell/mm3) and slightly above-normal protein levels
(40–50 mg/dL) in the cerebrospinal fluid (CSF) [35]. Par-
alytic poliomyelitis occurs in 0.1–1% of all PV infections,
depending on the offending serotype [132]. Based on the
specific manifestation, paralytic poliomyelitis without
apparent affect in sensation or cognition is classified as
either: (i) spinal poliomyelitis, characterized by acute flac-
cid paralysis secondary to selective destruction of spinal
motor neurons and subsequent dennervation of the asso-
ciated skeletal musculature; (ii) bulbar poliomyelitis, pre-
senting with paralysis of respiratory muscles following
attack of neurons in the brain stem that control breathing;
and (iii) bulbospinal poliomyelitis, exhibiting effects on
both the brain stem and spinal cord [26,35]. Among cases
of paralytic poliomyelitis, it is estimated that fatalities
result in 2–5% of children and 15–30% of adults, num-
bers which are drastically increased in cases featuring bul-
bar paralysis [35].
Isolation of PV from the CSF is diagnostic but seldom
achieved [35]. Additionally, the precise mechanism(s) of
PV invasion of the CNS is not well understood. Three
hypotheses for mechanisms utilized by the virus to gain
entry into the CNS have been proposed: (1) the virus
invades the CNS by retrograde axonal transport
[71,138,139]; (2) the virus crosses the blood-brain barrier
(BBB), presumably independent of the presence of the cel-
lular receptor for PV, CD155 [200]; and (3) the virus is
imported into the CNS by infected macrophages – the
Trojan horse mechanism [51,57]. In support of the theory
of CNS invasion due to permeation of the BBB, Yang and
colleagues found that PV accumulated in the CNS of
CD155 transgenic (tg) mice at a constant rate that was
markedly higher than the accumulation rate for albumin,
which is not believed to cross the BBB [200]. Earlier, Blin-
zinger et al., had interpreted their own finding of PV par-
ticles in endothelial cells forming part of the BBB to
indicate that the virus breached the CNS through its vas-
culature [15]. Following this line of thought, evidence for
entry of PV into the CNS via infected macrophages is
largely circumstantial, emerging from observations that
PV replicates in macrophages expressing CD155 [51,57]
and that macrophages infected with Visna virus [151] and
human immunodeficiency virus (HIV) [54] traverse the
BBB.
However, experimental evidence from studies in non-
human primates [22,23] and CD155 tg mice [62,138,165]
supports the hypothesis of CNS invasion mediated by ret-
rograde axonal transport along peripheral nerves. The
observations that paralysis of the injected limb can be pre-
vented by transection of the nerve linking the site of injec-
tion to the spinal cord, and that skeletal muscle injury
concurrent with PV infection predisposes to paralysis ini-
tially localizing to the afflicted limb (as observed in phe-
nomena denoted provocation poliomyelitis and
iatrogenic poliomyelitis) [71,131], strongly suggest a neu-
ral pathway for PV entry into the CNS. Specially strong
evidence supporting a neural pathway of CNS invasion
emerged from a study published by Ohka et al., in which
the authors reported recovery of intact 160S virion parti-
cles in the sciatic nerve of CD155 tg mice transected at var-
ious intervals following intramuscular inoculation with
PV, an observation suggesting a role for fast retrograde
axonal transport driving poliovirions along peripheral
nerves to the spinal cord, where the cell bodies of motor
neurons targeted by the virus reside [138]. This observa-
tion supported early reports of the presence of PV in axons
during experimental poliomyelitis [20,55].
Poliovirus vaccines
Prior to the 20th  century, virtually all children were
infected with PV while still protected by maternal anti-
bodies. In the 1900s, following the industrial revolution
of the late 18th and early 19th centuries, improved sanita-
tion practices led to an increase in the age at which chil-
dren first encountered the virus, such that at exposure
children were no longer protected by maternal antibodiesVirology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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[132]. Consequently, epidemics of poliomyelitis surfaced
[35].
In the mid-20th century, in efforts to combat the ever
growing epidemics of poliomyelitis ravaging the United
States, research focused on the design of vaccines as a
means of halting transmission. The first vaccine to be pro-
duced was the inactivated (or "killed") PV vaccine (IPV)
by Jonas Salk on April 12, 1955. In producing IPV, all
three PV serotypes were (and continue to be) grown in
vitro  in African green monkey kidney (Vero) cells and
inactivated by formaldehyde. IPV was shown to effectively
immunize and protect against poliomyelitis [35].
A second vaccine which was demonstrated to be both safe
and effective was the oral (or "live") PV vaccine (OPV)
developed by Albert Sabin in 1963. In truth, testing of the
vaccine began in 1957 under the auspices of the WHO,
but it was not until 1961 that the United States Public
Health Service endorsed OPV, then only produced in the
monovalent form. Trivalent OPV (or simply "OPV" as will
be referred to henceforth) became available in 1963 and,
owing to its unique ability to produce unmatched gas-
trointestinal immunity, thereby preventing infection with
wt virus, soon became the preferred PV vaccine in the
United States and many other countries. OPV is com-
posed of att strains of all three PV serotypes, grown in vitro
in Vero cells, in a 10:1:3 ratio of types 1:2:3, respectively
[35].
The att strains comprising OPV were generated by serial
passage of wt  strains at high multiplicity of infection
(MOI) in a series of hosts ranging from cells derived from
a variety of sources including monkey testis, kidney, and
skin to live monkeys [124], accompanied by selection of
variants following experimental bottlenecking events
such as single-plaque cloning and limiting dilution. The
desirable characteristics of selected variants were: (i) abil-
ity to replicate effectively in the gastrointestinal tract; (ii)
defectiveness in the ability to invade or replicate within
the CNS; and (iii) genetic stability so as to withstand the
pressures of replication within the human host without
reversion to a neurovirulent phenotype. These qualities
were those present in variants which came to be the Sabin
vaccine strains.
Years later, comparison of the nucleotide sequences of the
att Sabin strains and their neurovirulent parental strains
revealed a series of mutations, some of which were subse-
quently found to be responsible for the att phenotypes of
the Sabin strains. PV type 1 (Sabin) [PV1(S)] harbored 7
nucleotide substitutions localizing to the 5'NTR, 21
amino acid alterations within the polyprotein, and 2
nucleotide substitutions within the 3'NTR [157]. PV type
3 (Sabin) [PV3(S)] contained 2 nucleotide substitutions
in the 5'NTR, 4 amino acid changes within the polypro-
tein, and a single nucleotide deletion within the 3'NTR
[216]. Lastly, PV type 2 (Sabin) [PV2(S)] exhibited a single
nucleotide substitution within the 5'NTR as well as one
amino acid change within the polyprotein [115,147,164].
Subsequent sequence analysis of revertants with regained
neurovirulence indicated that mutations mapping to the
5'NTR specified the att  phenotype of the three Sabin
strains. Attenuating point mutations within the 5'NTR of
the Sabin vaccine strains (nt 480, 481, and 472 in sero-
types 1, 2, and 3, respectively) localize to the IRES
(domain V) (Fig. 2) and their presence has been linked to
deficiencies in viral replication in the CNS and in neurob-
lastoma cells [106,107] as well as reductions in transla-
tion of the viral mRNAs as compared to wt  sequences
[184-186].
Moreover, all Sabin strains exhibit ts phenotypes, which
map to the 5'NTR mutation (for all 3 types) [94,114,118],
to the capsid precursor (for all 3 types) [27,107,114,142],
as well as to the 3Dpol  coding sequence (for type 1)
[27,39,118,146,187,191]. The ts phenotype is thought to
be the most important trait of the vaccines to confer atten-
uation.
Poliovirus eradication and evolution
Thanks in part to the effectiveness and ease of administra-
tion of OPV as well as to the efforts of public health offi-
cials in the United States, the transmission of wt PV was
halted by 1979, less than 20 years since introduction of
OPV [35]. Indeed, OPV was the weapon of choice in the
fight against vaccine-preventable poliomyelitis of the Pan
American Health Organization (PAHO) under the leader-
ship of Ciro de Quadros, M.D., M.P.H. By transforming
vaccines and immunization against PV into a top priority
of governments, vaccine producers, and public health
experts, de Quadros was able to institute teams to further
his cause at the Ministry of Health in nearly every country
in the Americas. In 1985, PAHO announced its goal to
eradicate wt PV in the Western Hemisphere by 1990. The
target date was met. The last case of wt PV-induced para-
lytic poliomyelitis was documented in Peru in 1991.
Three years later, in 1994, the International Commission
for the Certification of Poliomyelitis Eradication
announced that transmission of wt PV in the Americas
had been discontinued.
Decades prior, while the United States was actively
attempting to halt transmission of wt PV by vaccination
with OPV, the WHO was trying to finalize the eradication
of another highly infectious agent – smallpox. By 1967,
programs to eradicate smallpox had proven successful in
many regions of the globe, including Western Europe,
North America, and Japan. In 1967, in line with recom-
mendations made by a WHO Expert Committee onVirology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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Smallpox 3 years earlier to vaccinate the entire world's
population as a means of furthering efforts to eradicate
the variola virus, the WHO introduced the Intensified
Smallpox Eradication Program. The mass vaccination
strategy employed to eradicate an agent, estimated to have
caused 10–15 million cases of smallpox as early as 1967,
eventually paid off. The last recorded case of smallpox
occurred in Somalia in 1979. In 1980, the 33rd World
Health Assembly announced the first successful eradica-
tion of a major human disease – smallpox [56].
In 1988, the WHO envisioned the eradication of yet
another agent causing major human disease (i.e., PV) by
launching a global campaign to eradicate wt PV by the
year 2000. Of the two available polio vaccines, the Sabin
OPV was chosen to further the planned eradication
efforts. Two characteristics of OPV propelled it for selec-
tion by the WHO as the instrument of choice in the Glo-
bal Polio Eradication Initiative: (1) its effectiveness in
producing gastrointestinal immunity; and (2) the fact that
no special instrumentation (i.e., needles) was required for
its administration.
Undoubtedly, the use of OPV in mass vaccinations has
resulted in dramatic reductions in the number of cases of
poliomyelitis due to infections with wt PV from an esti-
mated 350,000 in over 125 endemic countries in 1988 to
just 1,874 in 2006. But perhaps counter-intuitively, the
use of OPV now poses enormous challenges to this
endeavor. A major flaw of OPV is that it is genetically
unstable, a characteristic that makes it particularly suscep-
tible to evolve into circulating vaccine-derived poliovi-
ruses (cVDPV), exhibiting wt PV-like properties, including
neurovirulence. The Centers for Disease Control (CDC)
estimates that in the United States, while OPV was being
used, one case of vaccine-associated paralytic poliomyeli-
tis (VAPP) emerged for every 2 to 3 million doses of OPV
administered, which accounted for 8 to 10 cases of VAPP
in this country per year. In fact, in the United States, the
vast majority (95%) of cases of paralytic poliomyelitis
documented between 1980 and 1999 resulted from
cVDPV-induced VAPP [35]. In 1996, in order to reduce
the incidence of VAPP among vaccine recipients, the
United States Advisory Committee on Immunization
Practices (ACIP) recommended the increased use of IPV
by replacing the first two vaccine doses of the immuniza-
tion schedule with IPV as opposed to OPV. While the risk
of VAPP was reduced among vaccine recipients, the equiv-
alent reduction in risk did not translate for non-immune
contacts of vaccine recipients. With this in mind, in 1999,
the ACIP recommended that starting in the year 2000 use
of OPV be discontinued and that IPV be used exclusively
in the United States.
Specifically, genetic changes that would endow OPV with
wt PV phenotypes, transforming att vaccine strains into
cVDPV with the ability to cause VAPP among vaccine
recipients and/or their close contacts, could take the form
of reversions of known attenuating mutations and recom-
bination, whether inter- or hetero-typic [2]. Certainly, as
discussed above, comparisons of the nucleotide
sequences of wt PV strains with revertants of the att Sabin
OPV strains were key in identifying the determinants of
attenuation. But perhaps just as important in the genesis
of cVDPV is the possibility of recombination. Admittedly,
recombination among human enteroviruses has been
hypothesized to be a common occurrence in nature.
In fact, recombination between RNA viruses, a process
originally considered highly unlikely, was shown first
with polioviruses [82]. Later, Agol and his colleagues pro-
vided evidence that recombination can also occur
between different serotypes of PV [170,189]. Significantly,
the 3 Sabin vaccine strains have been shown to undergo
rampant intertypic recombination in vaccine recipients
[17,33,37,42,63,64,93,105,111,117,148]. Finally, recom-
bination between polioviruses was shown to occur in a
cell-free HeLa cell extract [49].
It has been speculated that recombination may serve as a
mechanism to augment the potential of viruses to adapt
and evolve. The evolution of OPV into highly diverged
cVDPV, via recombination between PV and other closely
related enteroviruses, in inadequately immunized popu-
lations is a very real concern [8,95,112,171,177]. For the
most part, recombinants between the Sabin vaccine
strains and other human enteroviruses exhibit crossover
points within the non-structural region of the genome,
such that the PV 5'NTR and structural P1 regions are
retained. Consequently, of particular concern are recom-
binations that results in viruses which have lost the att
phenotype of the parental vaccine strains and gained phe-
notypic characteristics that would make them indistin-
guishable from wt  PV, thereby acquiring the ability to
cause poliomyelitis.
Recently, in the current climate of attempting to eradicate
PV, the possibility of genetic exchanges between the Sabin
OPV strains and closely related viruses has come into the
limelight. Indeed the propensity of OPV strains to recom-
bine in recipients of the vaccine has been documented in
numerous outbreaks of VAPP secondary to the unchecked
circulation of cVDPV in poorly immunized communities
[8,95,112,171,177]. Moreover, the possibility exists that,
as previously hypothesized [[72,166]; Jiang P, Faase JAJ,
Toyoda H, Paul A, Gorbalenya AE, Wimmer E, unpub-
lished], in a world free of PV and anti-PV antibodies as
envisioned by the WHO, viruses closely related to the
polioviruses such as the C-cluster coxsackie A viruses (e.g.,Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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CAV20) may fill the niche left vacant by the polioviruses.
Could C-cluster coxsackie A viruses evolve to utilize
CD155 as a cellular receptor, thereby completely altering
the disease syndromes with which they would be associ-
ated? If only the structural region of C-cluster coxsackie A
viruses evolved to recognize the PV cellular receptor while
maintaining the rest of the genome unchanged, would
such a virus replicate in the same cell types and to the
same levels as wt PV or would the C-cluster coxsackie A
virus-specific genome segments impose cell-internal
restrictions on viral replication? If simply the presence of
C-cluster coxsackie A virus-derived genome segments
results in restricted viral replication, which particular
genome segments are accountable for such phenotypic
differences? Moreover, would attenuating mutations in
the PV genome translate into attenuating mutations in
viruses that result from the recombination of PV with a
closely-related yet non-neurovirulent C-cluster coxsackie-
virus? These are precisely some of the questions currently
under investigation in the Wimmer laboratory.
The biochemical synthesis of poliovirus
Despite the undeniable success of the Global Polio Eradi-
cation Initiate in the nineteen years since its introduction,
characteristics inherent to OPV, logistical obstacles in
ensuring 100% vaccination, as well as the realization that
de novo synthesis of viruses is a possibility, have brought
into question the feasibility of the control of poliomyelitis
by means of the total eradication of wt PV. Current recom-
mendations by the WHO include the cessation of OPV
vaccination 3 years following the last reported case of
poliomyelitis due to infection with wt PV. In time, cessa-
tion of vaccination would inevitably result in lost of herd
immunity, which in turn generates an ever increasing pool
of susceptible individuals to the same agent against which
immunization was originally targeted and to one similar
that is evolving to replace it. In such discussions, an
important consideration remains: can a virus that can be
synthesized ever truly be considered eradicated?
Evidence for the ability to chemically synthesize a virus
(i.e., PV) first emerged from a study published by Eckard
Wimmer's group in 2002 [34], which described the de
novo biochemical synthesis of infectious PV by utilizing as
instruction only the published nucleotide sequence of the
genome. The initial step in the scheme to synthesize
PV1(M) consisted of generating a complete complemen-
tary DNA (cDNA) copy of the virus genome bearing a
phage T7 RNA polymerase promoter at the 5' end. This
endeavor was accomplished by a laborious process in
which: (i) overlapping segments of 400 to 600 base pairs
(bp) were synthesized by piecing together purified oligo-
nucleotides (approximately 69 nt in length) of plus and
minus polarity with overlapping complementary
sequences at the ends, followed by ligation of the seg-
ments into a plasmid vector; (ii) cloned segments were
sequenced to pinpoint segments with correct sequences
and those containing only a small number of mutations
that could be corrected either by sub-cloning or by site-
directed mutagenesis; (iii) cloned segments were sequen-
tially joined to generate three large DNA fragments 3026,
1895, and 2682 bp in length; and (iv) combining the
three DNA fragments to produce the full-length sPV1(M)
cDNA. To ensure the wt sequence of PV1(M) could be dis-
tinguished from that of sPV1(M), in generating the
sPV1(M) cDNA, 27 nucleotide substitutions were engi-
neered as markers in the sPV1(M) cDNA. Next, the T7 pro-
moter-containing sPV1(M) cDNA was transcribed in vitro
with T7 RNA polymerase to yield highly infectious virus
RNA, which was equivalent in length to virion RNA. The
presence of all genetic markers engineered into the
sPV1(M) cDNA was established by restriction enzyme
digest analysis of products of reverse transcriptase-
polymerase chain reaction (RT-PCR) in which virus RNA
isolated from sPV1(M)-infected HeLa cells was used as
template. De novo synthesis of PV from transcript RNA
derived from sPV1(M) cDNA in a cell-free extract of unin-
fected HeLa cells, as previously described for wt PV1(M)
[146], was confirmed with the yield of end products of
proteolytic processing of the virus polyprotein as well as
the production of infectious virus. Comparison of virus-
specific proteins generated by incubation of sPV1(M)
cDNA-derived transcript RNA with an S3 cytoplasmic
extract of HeLa cells with the corresponding proteins
derived from wt  PV1(M) cDNA-derived transcript RNA
validated the products of in vitro translation as PV-specific
proteins. The production of infectious virus by incubation
of sPV1(M) cDNA-derived transcript RNA with an S3 cyto-
plasmic extract of HeLa cells was ascertained by analysis of
plaque formation on HeLa cell monolayers on which aliq-
uots of the transcript RNA-containing cytoplasmic extract
had been incubated. The ability of CD155-specific mono-
clonal antibody (mAb) D171 to block infection of HeLa
cells by sPV1(M) was verified by the observation that
incubation of HeLa cells with mAb D171 prior to addition
of sPV1(M) entirely voided the virus' plaque forming abil-
ity. Lastly, to characterize the disease-inducing potential
of sPV1(M), the neurovirulence phenotype of this virus
was examined in CD155 tg mice. Following intracerebral
(i.c.) inoculation with sPV1(M), adult CD155  tg mice
often developed neurological signs characteristic of polio-
myelitis, including flaccid paralysis and even death. The
inoculum required to produce paralysis and/or death in
half the mice inoculated (PLD50) was markedly increased
over that required to produce the same signs of disease
with wt PV1(M). The degree of attenuation of sPV1(M)
compared to the parental PV1(M) was rather unantici-
pated. All nucleotide substitutions engineered into the
sPV1(M) ORF, with the exception of XmaI and StuI restric-
tion sites generated in the 5'NTR and 2B regions, pro-Virology Journal 2007, 4:70 http://www.virologyj.com/content/4/1/70
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duced silent mutations. But the changes in the 2B coding
region had previously been demonstrated not to influence
virus replication in vitro [126,198]. Hence, when the find-
ings were first published, the authors attributed the att
phenotype of sPV1(M) in CD155 tg mice to the silent
mutations and then unidentified mechanisms [34].
In a subsequent study [43], the authors set forth to deter-
mine what aspect of the sPV1(M) genome was responsible
for the phenotypic changes observed in comparisons with
wt PV1(M). In collaboration with others the author of this
review showed that a single nucleotide substitution
(A103G) mapping to the spacer region between the clover-
leaf and the IRES within the 5'NTR determines the att phe-
notype of sPV1(M).
In our quest to determine what alterations in the genotype
of sPV1(M) resulted in the observed neurophenotypic
changes, two strategies were employed: (1) exchange of
genomic segments between sPV1(M) and wt PV1(M) fol-
lowed by analysis of neurovirulence in vivo; and (2)
sequence analysis of viruses recovered from the spinal
cords ofsPV1(M)-inoculated CD155 tg mice that had suc-
cumbed to infection in concert with comparison of these
sequences with that of sPV1(M) virus that constituted the
inoculum. In all instances, we identified a change at one
locus in the sequences of recovered viruses. Analyses of
the in vitro phenotypes in tissue culture as well as the in
vivo phenotypes in CD155 tg mice of a series of PV variants
revealed the critical nucleotide in determining two impor-
tant characteristics of sPV1(M): (i) an att neurophenotype
in adult CD155 tg mice; and (ii) a ts phenotype in neuro-
nal cells of human origin.
Considering that the nucleotide we identified as an
important determinant of the replicative phenotypes of
PV in vivo as well as in vitro (A103) is highly conserved
among polioviruses and human C-cluster coxsackie A
viruses and that, in evolution, conservation often equates
with functional importance, we have continued our anal-
ysis of this locus to studying the effect of mutating this
nucleotide (A103G) in CAV20 – one of three human C-
cluster enteroviruses exhibiting the highest degree of
sequence homology to the polioviruses [De Jesus N, Jiang
P, Cello J, Wimmer E, unpublished].
Conclusion
Whether accidentally or not, over centuries poliovirus has
evolved to specifically target alpha motor neurons in the
spinal cord of its human host, thereby causing acute flac-
cid paralysis, the characteristic sign of paralytic poliomye-
litis. Fortunately, since its inception in 1988, the WHO's
Global Polio Eradication Initiative, along with great eco-
nomic and intellectual efforts, has served to greatly reduce
the number of documented cases of poliomyelitis world-
wide. Nonetheless, the ultimate goal of halting poliovirus
transmission as a means of eradicating poliomyelitis has
proven rather elusive. In light of this realization and con-
sidering the possibility that a virus that can be synthesized
may never truly be considered eradicated, it is imperative
that new strategies to combat poliovirus be considered,
whether these be in the form of the development of new
vaccines and/or anti-viral drugs. In this endeavor it is
important that aspects of the pathogenesis of this virus,
such as interactions with host factors that play roles in
replication and/or translation of the viral genome be
identified, as well as sites of primary replication and the
mechanism(s) of CNS invasion be more clearly eluci-
dated. For it is only by understanding the intricacies of the
life cycle of this pathogen within the human host that we
will be able to more effectively develop new treatment
modalities.
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